Gastrointestinal Cancer Clinical Trials & Research at St. Joseph Health
Medical Group
St. Joseph Health Medical Group is currently enrolling patients for the
following gastrointestinal cancer clinical trials:
Gastric Cancer
Colorectal Cancer
Gastric
A Phase 3, Double-blind, Randomized Study of BGB-290 versus Placebo as
Maintenance Therapy in Patients with Inoperable Locally Advanced or Metastatic
Gastric Cancer that Responded to Platinum-based First-line Chemotherapy (BeiGene)
Phase III
The purpose of this study is to compare the efficacy and safety of single
agent poly (ADP-ribose) polymerase (PARP) inhibitor BGB-290 to placebo
as maintenance therapy in subjects with advanced or inoperable gastric
cancer who have responded to first line platinum based chemotherapy. Subjects
are randomized 1:1 to BGB-290 (Arm A) or placebo (Arm B). Patients must
have achieved a partial response that is maintained for ≥ 4 weeks or
a complete response with platinum-based first-line chemotherapy.
Treatment agent: BGB-290 (PARPi)
PI:
Thomas Stanton, MD
Study Coordinator: Sabine Ucik //
Sabine.Ucik@stjoe.org // (707) 521-3830
Resources and Links:
clinicaltrials.gov NCT No: NCT03427814
Colorectal
A Phase 3, double-blind, multicenter, placebo-controlled study of PledOx
used on top of modified FOLFOX6 (5-FU/FA and Oxaliplatin) to prevent chemotherapy
induced peripheral neuropathy (CIPN) in patients with first-line metastatic
colorectal cancer (POLAR)
Phase III
This is a multicenter, double-blind, placebo-controlled study to establish
the efficacious dose of PledOx in prevention of chronic chemotherapy induced
peripheral neuropathy (CIPN) induced by oxaliplatin. Patients with metastatic
colorectal cancer (CRC), who are indicated for first-line modified FOLFOX-6
(mFOLFOX6) chemotherapy for at least 3 months, without any pre-planned
treatment breaks, will be randomized in a 1:1:1 ratio to one of three
treatment arms: PledOx (2 μmol/kg) + mFOLFOX6 chemotherapy; PledOx
(5 μmol/kg) + mFOLFOX6 chemotherapy; Placebo + mFOLFOX6 chemotherapy.
The addition of an appropriate biologic therapy will be left to the discretion
of the Investigator.
Treatment agent: mFOLFOX6 + PledOX vs mFOLFOX6 + placebo
PI:
Thomas Stanton, MD
Study Coordinator: Camille Shaffer //
Camille.Shaffer@stjoe.org // (707) 521-3809
Resources and Links:
clinicaltrials.gov NCT No: NCT03654729